sorafenib has been researched along with Germinoblastoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Brendehaug, A; Eek, AK; Forthun, RB; Hovland, R; Høysæter, T; Munthe-Kaas, MC; Osnes, LTN; Prescott, T; Spetalen, S | 1 |
| Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E | 1 |
| Chang, YF; Chuang, HY; Hwang, JJ; Liu, RS | 1 |
| Alfaro, V; Aspeslagh, S; Bahleda, R; Extremera, S; Fudio, S; Gyan, E; Hollebecque, A; Salles, G; Soria, JC; Soto-Matos, A; Stein, M | 1 |
| Ambrosini, V; D'Errico-Grigioni, A; Fanti, S; Fini, M; Franchi, R; Giavaresi, G; Malvi, D; Nanni, C; Quarta, C; Torricelli, P; Zinzani, PL | 1 |
| Anichini, A; Barbati, C; Carlo-Stella, C; Corradini, P; Devizzi, L; Di Nicola, M; Dodero, A; Farina, L; Gianni, AM; Guidetti, A; Lanocita, R; Locatelli, SL; Malorni, W; Marchianò, A; Matteucci, P; Mortarini, R; Pierdominici, M; Tarella, C | 1 |
| Clemetson, KJ | 1 |
2 trial(s) available for sorafenib and Germinoblastoma
| Article | Year |
|---|---|
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Depsipeptides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Niacinamide; Peptides, Cyclic; Phenylurea Compounds; Prospective Studies; Sorafenib; Young Adult | 2017 |
Phase II study of sorafenib in patients with relapsed or refractory lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lymphoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Young Adult | 2012 |
5 other study(ies) available for sorafenib and Germinoblastoma
| Article | Year |
|---|---|
Partial Response to Sorafenib in a Child With a Myeloid/Lymphoid Neoplasm, Eosinophilia, and a ZMYM2-FLT3 Fusion.
Topics: Antineoplastic Agents; Child, Preschool; Eosinophilia; fms-Like Tyrosine Kinase 3; Humans; Lymphoma; Male; Nuclear Proteins; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Sorafenib | 2021 |
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Survival; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma; MAP Kinase Signaling System; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Niacinamide; Pericytes; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Administration Schedule; Immunosuppressive Agents; Immunotherapy, Adoptive; Lymphoma; Mice; Mice, Transgenic; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Microenvironment | 2014 |
18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Humans; Lymphoma; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Pyridines; Radiopharmaceuticals; Sorafenib; Treatment Outcome | 2010 |
American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA.
Topics: Anemia, Sickle Cell; Antibiotics, Antineoplastic; Antigens, CD20; Benzamides; Benzenesulfonates; CD40 Antigens; Diphenylamine; Hematologic Neoplasms; Hematology; Humans; Ki-1 Antigen; Leukemia, Myeloid; Lymphoma; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib | 2007 |